Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | OGA | O60502 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598920 | 0.86 | TSHR (0.40) | PIK3CGLMNAGAAMAPTHPGD | |
| SCHEMBL1770530 | 0.83 | HCAR3 (0.41) | PIK3CGLMNAGAAMAPTHPGD | |
| SCHEMBL1770199 | 0.81 | ALDH1A1 (0.39) | PIK3CGLMNAGAAMAPTHPGD | |
| SCHEMBL692071 | 0.78 | TSHR (0.37) | LMNAGAAMAPTCYP3A4ALDH1A1 | |
| SCHEMBL1770594 | 0.77 | PIK3CG (0.40) | PIK3CGLMNAGAAMAPTHPGD | |
| SCHEMBL1770533 | 0.77 | HCAR3 (0.38) | LMNAMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL12598910 | 0.77 | ALDH1A1 (0.39) | PIK3CGLMNAGAAMAPTHPGD | |
| SCHEMBL1770505 | 0.76 | ALDH1A1 (0.39) | PIK3CGLMNAGAAMAPTHPGD | |
| SCHEMBL693037 | 0.76 | HCAR3 (0.39) | PIK3CGLMNAGAAMAPTHPGD | |
| SCHEMBL1770509 | 0.76 | HCAR3 (0.36) | LMNAMAPTHPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421871-B1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | CCNA1, MKI67, CCNT1 | PIK3CG 4763/4885LMNA 3302/4885GAA 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.